Search results for "Hyla"

showing 10 items of 2227 documents

Epigenetic changes underlie the aggressiveness of histologically benign meningiomas that recur

2019

Meningiomas are the most frequent primary brain tumor. Usually, they are curable by surgery, but even after seemingly complete resection, some low-grade lesions recur. Despite recent improvements, signatures having prognostic value in grade I tumors remain poorly characterized. The frequency and delicate location of these tumors suggest that the risk of recurrence might be more accurately predicted. Herein, we show an easy way to evaluate the methylation status of meningiomas and its correlation with the prognosis of the disease. A series of 120 meningiomas, including primary tumors and recurrences, were analyzed histopathologically, and 24 tumor suppressor genes (TSGs) were studied by meth…

AdultMale0301 basic medicineOncologymedicine.medical_specialtyAdolescentBrain tumorDiseaseMLH1Epigenesis GeneticPathology and Forensic MedicineMeningiomaYoung Adult03 medical and health sciences0302 clinical medicineCDKN2BInternal medicineMeningeal NeoplasmsmedicineHumansGenes Tumor SuppressorClinical significanceChildAgedAged 80 and overbusiness.industryDNA MethylationMiddle Agedmedicine.disease030104 developmental biology030220 oncology & carcinogenesisBenign MeningiomaDNA methylationFemaleNeoplasm Recurrence LocalMeningiomabusinessHuman Pathology
researchProduct

Topical azithromycin for the prevention of Lyme borreliosis: a randomised, placebo-controlled, phase 3 efficacy trial

2017

Summary Background Lyme borreliosis develops in 1–5% of individuals bitten by ticks, but with a diagnostic gap affecting up to 30% of patients, a broadly applicable pharmacological prevention strategy is needed. Topical azithromycin effectively eradicated Borrelia burgdorferi sensu lato from the skin in preclinical studies. We assessed its efficacy in human beings. Methods In this randomised, double-blind, placebo-controlled, multicentre trial done in 28 study sites in Germany and Austria, adults were equally assigned to receive topical 10% azithromycin or placebo twice daily for 3 consecutive days, within 72 h of a tick bite being confirmed. Randomisation numbers, which were stratified by …

AdultMale0301 basic medicinemedicine.medical_specialty030106 microbiologyPopulationAzithromycinAzithromycinPlacebolaw.invention03 medical and health sciencesTicksDouble-Blind MethodRandomized controlled triallawGermanyInternal medicinemedicineClinical endpointAnimalsHumansTreatment FailureSeroconversioneducationLyme Diseaseeducation.field_of_studybusiness.industryAntibiotic ProphylaxisMiddle Agedbacterial infections and mycosesAnti-Bacterial AgentsSurgeryClinical trialInfectious DiseasesBorrelia burgdorferiErythema migransFemalebusinessmedicine.drugThe Lancet Infectious Diseases
researchProduct

Urea cycle dysregulation in non-alcoholic fatty liver disease.

2018

Background & Aims: In non-alcoholic steatohepatitis (NASH), the function of urea cycle enzymes (UCEs) may be affected, resulting in hyperammonemia and the risk of disease progression. We aimed to determine whether the expression and function of UCEs are altered in an animal model of NASH and in patients with non-alcoholic fatty liver disease (NAFLD), and whether this process is reversible. Methods: Rats were first fed a high-fat, high-cholesterol diet for 10 months to induce NASH, before being switched onto a normal chow diet to recover. In humans, we obtained liver biopsies from 20 patients with steatosis and 15 with NASH. Primary rat hepatocytes were isolated and cultured with free fatty …

AdultMale0301 basic medicinemedicine.medical_specialtyCarbamoyl-Phosphate Synthase (Ammonia)Ornithine transcarbamylase03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAmmoniaGlutamate-Ammonia LigaseNon-alcoholic Fatty Liver DiseaseInternal medicineGene expressionmedicineAnimalsHumansUreaRats WistarPromoter Regions GeneticCells CulturedOrnithine CarbamoyltransferaseAgedHepatologyChemistryFatty liverHyperammonemiaDNA MethylationMiddle Agedmedicine.diseaseRats030104 developmental biologyEndocrinologyLiverUrea cycleHepatocytesUreaFemale030211 gastroenterology & hepatologySteatohepatitisSteatosis
researchProduct

Is telephone follow-up really effective in early diagnosis of inflammatory complications after tooth extraction?

2018

Background To establish whether telephone follow-up is really able to intercept post-extraction complications and to evaluate the degree of patient satisfaction with this kind of post-surgical monitoring. Material and Methods Six hundred and thirty-eight patients were enrolled and randomly assigned to a test or control group. Test group patients were monitored by telephone follow-up 24 and 72 hours after surgery to investigate the presence of local symptoms that are frequently associated with surgical wound infection and inflammation. Both test and control group patients were examined 7 days at suture removal. Patients with systemic diseases, those in which intra-operative accidents occurre…

AdultMale0301 basic medicinemedicine.medical_specialtycomplicationsoral surgery; complications; telephone follow-upDehiscencelaw.inventionSettore MED/28 - MALATTIE ODONTOSTOMATOLOGICHE03 medical and health sciencesPostoperative ComplicationsPatient satisfactionRandomized controlled trialSuture (anatomy)lawtelephone follow-upHumansSurgical Wound Infectionfollow upMedicineAntibiotic prophylaxisGeneral DentistryInflammationbusiness.industryResearchSurgical wound:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseTelephoneSurgeryEarly DiagnosisOtorhinolaryngologyPatient SatisfactionTooth ExtractionUNESCO::CIENCIAS MÉDICASFemaleSurgery030101 anatomy & morphologyOsteitisbusinessComplicationFollow-Up Studiesoral surgeryMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: Prospective results from a multi-center study

2021

Background Thrombosis and pulmonary embolism appear to be major causes of mortality in hospitalized coronavirus disease 2019 (COVID-19) patients. However, few studies have focused on the incidence of venous thromboembolism (VTE) after hospitalization for COVID-19. Methods In this multi-center study, we followed 1529 COVID-19 patients for at least 45 days after hospital discharge, who underwent routine telephone follow-up. In case of signs or symptoms of pulmonary embolism (PE) or deep vein thrombosis (DVT), they were invited for an in-hospital visit with a pulmonologist. The primary outcome was symptomatic VTE within 45 days of hospital discharge. Results Of 1529 COVID-19 patients discharge…

AdultMaleARDSmedicine.medical_specialtyTime FactorsDeep veinIran030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRisk FactorsFull Length ArticleInternal medicinemedicineHumansProspective Studiescardiovascular diseasesMyocardial infarctionThromboprophylaxisStrokeAgedAged 80 and overVenous Thrombosisbusiness.industryIncidenceIncidence (epidemiology)COVID-19Venous ThromboembolismHematologyMiddle Agedmedicine.diseaseThrombosisPatient DischargePulmonary embolismHospitalizationmedicine.anatomical_structure030220 oncology & carcinogenesisHeart failureFemaleCohort studyPulmonary EmbolismbusinessThrombosis Research
researchProduct

High-Concentration Liquid Prednisolone Formula: Filling a Therapeutic Niche in Severe Acute Attacks of Urticaria and Angioedema.

2015

<b><i>Background/Aims:</i></b> According to current guidelines, the emergency kit for patients with severe urticaria and/or angioedema should include a corticosteroid with a prednisolone-equivalent of 50-100 mg. Since severe dysphagia may occur in anaphylaxis, liquid corticosteroids are advantageous. Presently, only liquid preparations with less than 100 mg prednisolone equivalent are available worldwide. <b><i>Methods:</i></b> We prepared a highly concentrated liquid prednisolone formula for oral administration (1 or 5 mg prednisolone per ml). We observed efficacy and safety of 100 mg or >250 mg liquid oral prednisolone in comparison to in…

AdultMaleAdolescentUrticariaPhysiologymedicine.drug_classmedicine.medical_treatmentPrednisoloneAnti-Inflammatory AgentsAdministration OralDermatologyDosage form030207 dermatology & venereal diseases03 medical and health sciencesYoung Adult0302 clinical medicineOral administrationmedicineHumansAngioedemaAgedPharmacologyHigh concentrationDosage FormsAngioedemabusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseTreatment Outcome030228 respiratory systemIntravenous therapyAnesthesiaPrednisoloneCorticosteroidFemalemedicine.symptombusinessAnaphylaxismedicine.drugSkin pharmacology and physiology
researchProduct

Lack of neurofibromatosis type 2 gene promoter methylation in sporadic vestibular schwannomas.

2011

<i>Background:</i> Vestibular schwannomas (VS) are benign tumors of the nervous system that are usually sporadic but also occur in the inherited disorder neurofibromatosis type 2 (NF2). In VS, losses of chromosomal material and mutations of the NF2 gene have been established to be causative. For a subset of VS without detectable gene alterations, promoter inactivation by hypermethylation has been suggested. However, published data are very limited and contradictory. <i>Methods:</i> We analyzed NF2 gene promoter methylation in 35 sporadic VS by methylation-specific PCR. <i>Results:</i> Twenty-three of the tumors were informative, showing no promoter methyl…

AdultMaleBiologymedicine.disease_causePolymerase Chain Reactionchemistry.chemical_compoundYoung Adultotorhinolaryngologic diseasesmedicineHumansNeurofibromatosis type 2NeurofibromatosisGeneAgedRetrospective StudiesMutationNeurofibromin 2PromoterMethylationDNA NeoplasmNeuroma AcousticDNA MethylationMiddle Agedmedicine.diseaseOtorhinolaryngologychemistryDNA methylationMutationCancer researchDisease ProgressionFemaleDNAFollow-Up StudiesORL; journal for oto-rhino-laryngology and its related specialties
researchProduct

Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres.

2010

Abstract Purpose: Quantitative methylation-specific tests suggest that not all cells in a glioblastoma with detectable promoter methylation of the O6-methylguanine DNA methyltransferase (MGMT) gene carry a methylated MGMT allele. This observation may indicate cell subpopulations with distinct MGMT status, raising the question of the clinically relevant cutoff of MGMT methylation therapy. Epigenetic silencing of the MGMT gene by promoter methylation blunts repair of O6-methyl guanine and has been shown to be a predictive factor for benefit from alkylating agent therapy in glioblastoma. Experimental Design: Ten paired samples of glioblastoma and respective glioblastoma-derived spheres (GS), c…

AdultMaleCancer ResearchMethyltransferaseDNA repairBiologyDNA methyltransferaseGene dosageO(6)-Methylguanine-DNA MethyltransferaseGene FrequencyTumor Cells CulturedHumansPromoter Regions GeneticneoplasmsAgedAged 80 and overBrain NeoplasmsO-6-methylguanine-DNA methyltransferaseMethylationDNA MethylationMiddle AgedMolecular biologydigestive system diseasesChromatinOncologyCpG siteDNA methylationFemaleGlioblastomaClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

Demethylation treatment restores hic1 expression and impairs aggressiveness of head and neck squamous cell carcinoma.

2010

Promoter hypermethylation of tumor suppressor genes is a common feature of primary cancer cells. However, at date the somatic epigenetic events that occur in head and neck squamous cell carcinoma (HNSCC) tumorigenesis are not yet been well defined. In the present study we analysed the methylation status of the gene hypermethylated in cancer-1 (hic1), a gene located on chromosome 17p13.3, a region frequently lost in HNSCC. We analysed 22 HNSCC samples and three cell lines using methylation specific PCR (MSP). We found hic1 methylated in 21 out of 22 samples and in all three cell lines. Treatment of the cell lines with the demethylating agent 5-Azacytidin (5-Aza) resulted in the demethylation…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyAntimetabolites AntineoplasticTumor suppressor geneBisulfite sequencingKruppel-Like Transcription FactorsBiologymedicine.disease_causechemistry.chemical_compoundCell Line TumormedicineHumansGenes Tumor SuppressorNeoplasm InvasivenessPromoter Regions GeneticneoplasmsAgedMethylationDNA MethylationMiddle Agedmedicine.diseaseHead and neck squamous-cell carcinomaDemethylating agentGene Expression Regulation Neoplasticstomatognathic diseasesOncologychemistryEpidermoid carcinomaHead and Neck NeoplasmsCancer cellCancer researchAzacitidineCarcinoma Squamous CellFemaleOral SurgeryCarcinogenesisOral oncology
researchProduct

Correlation between GP-170 expression, prognosis, and chemoresistance of superficial bladder carcinoma.

2003

To study GP-170 in superficial bladder cancer at initial diagnosis and at recurrence and to evaluate if intravesical chemoprophylaxis modifies the expression of GP-170 in tumor recurrences. GP-170 was retrospectively assessed in 160 patients affected by primary superficial transitional cell carcinoma of the bladder and followed for up to 10 years. Eighty-four patients (52.5%) recurred after transurethral resection (TUR). Adjuvant intravesical chemotherapy after TUR was adopted in 52 patients. The correlations between GP-170 and G-grade, T-category, risk of recurrence and of progression, and adoption of adjuvant intravesical chemotherapy were investigated. The correlations between variations…

AdultMaleCancer Researchmedicine.medical_specialtyPathologymedicine.medical_treatmentUrologySettore MED/24 - UrologiaSuperficial bladder carcinoma GP-170 MDR-1 Prognosis Intravesical chemotherapyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansATP Binding Cassette Transporter Subfamily B Member 1Stage (cooking)AgedRetrospective StudiesChemotherapyHematologyUrinary bladderbusiness.industryGeneral MedicineMiddle Agedmedicine.diseasePrognosisDrug Resistance MultipleGene Expression Regulation NeoplasticTransitional cell carcinomamedicine.anatomical_structureOncologyUrinary Bladder NeoplasmsChemotherapy AdjuvantDrug Resistance NeoplasmChemoprophylaxisFemaleSuperficial Bladder CarcinomaGenes MDRNeoplasm Recurrence LocalbusinessFollow-Up StudiesJournal of cancer research and clinical oncology
researchProduct